Prognostic implications of GP3a glucoprotein gene PLA1/PLA2 allele in prostatic cancer: pilot results of the study


Cite item

Full Text

Abstract

We studied the role of integrins, primarily, the role of allele distribution of GP3a gene in development of prostatic cancer (PC) and assessment of its prognostic significance. From November 2003 to May 2004 we examined 32 patients with PC: 11 patients with local PC T1-2N0M0; 14 patients with locally advanced cancer T3N0M0 and 7 patients with invasive and/or metastatic cancer T3-4N1M0-1 or T3-4N0-1M1. The blood from all the patients we studied with PCR for alleles of GP3a gene, PSA. Seventeen patients were found to have alleles PLAIAI, 14(44%) - alleles PLA1A2, 1(3%) - alleles PLA2A2. Alleles PLA1A2 occurred significantly more often than in the population (p < 0.005). The group analysis has found that 8 patients with local PC had alleles PLAIAI, 3 patients - alleles PLA1A2 (27%). We discovered alleles PLA2A2, PLAIAI and PLA1A2 in 1(7%), 5(36%) and 8(57%) patients with locally advanced PC, respectively. Among patients with metastatic and/or invasive prostatic cancer, there were 4 (57%) and 3 (43%) cases of alleles PLAIAI and PLA1A2, respectively. Our study demonstrated influence of carriage of PLA2 allele on occurrence of PC risk (5-fold higher) and its invasive forms (10-fold higher and more). Probability to develop local invasion among patients with prostatic cancer - carriers allele PLA1A2 is 6 times higher than among carriers of alleles PLAIAI. A PC course in carriers of alleles PLA1A2 may be characterized by faster development of local invasion and metastasizing vs carriers of alleles PLAIAI. These findings can be used in design of nomograms for prognostication of invasion of clinically small tumors in verification of significance on greater number of the patients.

References

  1. Лопаткин Н. А. (ред.) Руководство по урологии. М.: Медицина; 1998; т. 3: Рак предстательной железы.
  2. Гориловский Л. М., Телешова С. С. Рак предстательной железы. В кн.: Гориловский Л. М. (ред.) Избранные главы гериатрической урологии. М.: Ньюдиамед; 2000. 202-226.
  3. Аксель Е. М., Матвеев Б. П. Состояние онкоурологической помощи больным в России, 1997 г. Клин, онкол 1999' I (1): 3-5.
  4. Jemal A., Murray Т., Samuels A. et al. Cancer statistics, 2003. CA. Cancer J. Clin. 2003; 53: 5-40.
  5. Лоран О. Б., Пушкарь Д. Ю., Степанов В. И., Крохотина Л. В. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простатспецифического антигена сыворотки крови. М.; 1999.
  6. Jemal A., Thomas A., Murray Т., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 2002; 52: 23-56.
  7. Матвеев Б. П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы. М; 1999.
  8. Dunn J. К., Stamey Т. A., Scardino P. T. The pathologic features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol. (Baltimore) 1994; 152: 1714-1717.
  9. Noguchi M., Stamey T. A., McNeal J. E., Yemoto С. М. Relationship between systemic biopsies and histologic fettures of 222 radical prostatectomy specimens: lack of prediction of tumor significance for man with nonpalpable prostate cancer. J. Urol. (Baltimore) 2001; 166: 104-109.
  10. Gonsalgo M. L., Isaacs W. B. Molecular pathways to prostate cancer. J. Urol. (Baltimore) 2003; 170: 2444-2452.
  11. Cheng L., Nagabhushan M., Pretlow T. P. et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol. 1996; 148: 1375-1380.
  12. Trikha M., Timar J., Zacharek A. et al. Role for beta3 integrins in human melanoma growth and survival. Int. J. Cancer 2002; 101 (2): 156-167.
  13. Trikha M., Raso E., Cat Y. et al. Role of alphall(b)beta3 integrin in prostate cancer metastasis. Prostate 1998; 35 (3): 185-192.
  14. Hynes R. O. Cell 1987; 48: 549-554.
  15. Parsons J. Т., Parsons S. J. Curr. Opin. Cell Biol. 1997; 9: 187192.
  16. Clark E. A., Brugge J. S. Science 1995; 268: 233-238.
  17. Hynes R. O. Cell 1992; 69: 11-25.
  18. Weinberg R. A. Cancer Res. 1989; 49: 3713-3721.
  19. Fang F., Orend G., Watanabe N. et al. Science 1996; 271: 499- 502.
  20. Kumar С. С. Oncogene 1998; 17: 1365-1374.
  21. Nikiforov M. A., Hagen K., Ossovskaya V. S. et al. Oncogene 1996; 13: 1709-1719.
  22. Wu R. C., Schonthal A. H. J. Biol. Chem. 1997; 14: 2909129098.
  23. Ровенский Ю. А. Клеточные и молекулярные механизмы опухолевой инвазии. Биохимия 1998; 63 (9): 1204-1221.
  24. Mulcahy L. S., Smith M. R., Stacey D. W. Requirements for ras proto-oncogene function during serum-stimulated growth of N1H3T3 cells. Nature 1985; 313: 241-243.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2005 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies